Current Report Filing (8-k)
May 15 2017 - 7:35AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2017
ALDEYRA THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
001-36332
|
|
20-1968197
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
131 Hartwell Avenue, Suite 320
Lexington, MA 02421
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (781)
761-4904
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this
chapter).
Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☒
Item 2.02.
|
Results of Operations and Financial Condition.
|
On May 15, 2017, Aldeyra
Therapeutics, Inc. (Aldeyra) issued a press release and is holding a conference call regarding its financial results for the quarter ended March 31, 2017. The press release is furnished as Exhibit 99.1 to this Current Report on
Form 8-K and
is incorporated by reference herein.
Various statements to be made during the
conference call are forward-looking statements under the securities laws, including, but not limited to, statements regarding Aldeyras plans for its product candidates. In some cases, you can identify forward looking statements by
terms such as, but not limited to, may, might, will, objective, intend, should, could, can, would, expect, believe,
anticipate, project, target, design, estimate, predict, potential, plan or the negative of these terms, and similar expressions intended to identify
forward-looking statements. Such forward- looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.
Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could
cause actual results to differ materially from those reflected in Aldeyras forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyras clinical trials, the timing and success of
preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyras product candidates, and the labeling for
any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyras product candidates; the size and growth of the potential markets for Aldeyras product candidates and the ability to serve those
markets; Aldeyras expectations regarding Aldeyras expenses and revenue, the sufficiency of Aldeyras cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyras product
candidates; Aldeyras expectations regarding competition; Aldeyras anticipated growth strategies; Aldeyras ability to attract or retain key personnel; the anticipated trends and challenges in Aldeyras business and the market
in which it operates; and other factors that are described in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of Aldeyras Annual Report on
Form 10-K for
the year ended December 31, 2016, which is on file with the Securities and Exchange Commission (SEC) and available on the SECs website at www.sec.gov. Additional information will
also be set forth in those sections of Aldeyras Quarterly Report on
Form 10-Q for
the quarter ended March 31, 2017, which will be filed with the SEC in the second quarter of 2017.
In addition to the risks described above and in Aldeyras other filings with the SEC, other unknown or unpredictable factors also could
affect Aldeyras results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information conveyed on the conference call is provided only as of the date of the call, and
Aldeyra undertakes no obligation to update any forward-looking statements presented on the call on account of new information, future events, or otherwise, except as required by law.
The information in Item 2.02 of this Current Report on
Form 8-K and
the Exhibit attached
hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
ALDEYRA THERAPEUTICS, INC.
|
|
|
By:
|
|
/s/ Todd C. Brady, M.D., Ph.D.
|
Name:
|
|
Todd C. Brady, M.D., Ph.D.
|
Title:
|
|
President and Chief Executive Officer
|
Dated: May 15, 2017
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024